7Baggers
 PepGen (PEPG) Price Target Increased by 17.65% to 10.20  Nasdaq Mon, 17 Nov 2025 02:52:00 GMT
 PepGen receives U.S. patent for myotonic dystrophy drug candidate By Investing.com  Investing.com Nigeria Thu, 13 Nov 2025 05:30:11 GMT
 PepGen Inc. Strengthens Financial Position Amid Ongoing Losses  TipRanks Thu, 13 Nov 2025 04:55:50 GMT
 PepGen Narrows Losses And Advances Myotonic Dystrophy Research  Finimize Wed, 12 Nov 2025 13:13:27 GMT
 pepgen receives u.s. patent for myotonic dystrophy drug candidate  Investing.com India Wed, 12 Nov 2025 13:05:19 GMT
 PepGen reports Q3 EPS (52c), consensus (56c)  TipRanks Wed, 12 Nov 2025 12:48:42 GMT
 PepGen announces issuance of patent for PGN-EDODM1  TipRanks Wed, 12 Nov 2025 12:47:54 GMT
 Biotech firm PepGen's Q3 net loss narrows to $18 mln  MarketScreener Wed, 12 Nov 2025 12:14:01 GMT
 PepGen Inc. Reprices Underwater Stock Options  TipRanks Fri, 07 Nov 2025 08:00:00 GMT
 PepGen to Participate in Upcoming Investor Conferences  Business Wire Mon, 03 Nov 2025 08:00:00 GMT

PepGen Inc.
(NASDAQ:PEPG) 

PEPG stock logo

PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious neurological and neuromuscular diseases. The company is headquartered in Cambridge, Massachusetts.

Founded: 2018
IPO Price: $12 (May 06, 2022)
Sector: TECHNOLOGY
Industry: GENERAL

Share this website to your friends